Multiple recent studies also revealed that multiple myeloma (MM) cells with higher baseline expression of MCL1 more easily develop venetoclax resistance and show a lower response to even the initial phase of treatment (19–21). This evidence concerns the gene MCL1 and plasma cell myeloma.